These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3472651)

  • 1. Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line.
    Kees UR
    Cancer Res; 1987 Jun; 47(12):3088-91. PubMed ID: 3472651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE; Plunkett W; Linker CA
    Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
    Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
    Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete remission obtained in refractory acute lymphocytic leukemia using high-dose cytosine arabinoside combined with low-dose L-asparaginase].
    Inagaki C; Ito K; Omori I; Shimazaki C; Nishio A; Haruyama H; Isemura T; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):379-82. PubMed ID: 3855616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.